NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note published on Friday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NASDAQ:NURO opened at $4.31 on Friday. The stock’s 50-day moving average is $4.05 and its 200 day moving average is $3.90. The company has a market cap of $8.78 million, a PE ratio of -0.94 and a beta of 2.20. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73.

NeuroMetrix (NASDAQ:NURO) last announced its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. The company had revenue of $0.59 million for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same quarter last year, the firm earned ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.